FOR IMMEDIATE RELEASE

Xylonix and Invitrocue Form Strategic Clinical Alliance to Validate New Method for Combating IL-6 Pathologies

SINGAPORE, April 28, 2026 — Xylonix PTE. LTD. ("Xylonix") and Invitrocue PTE. LTD. ("Invitrocue") today announced the formation of a strategic clinical partnership to validate a transformative method for combating Interleukin-6 (IL-6) pathologies. This alliance marks the first public disclosure of the collaboration between the two companies, integrating a high-stakes clinical research program with an exclusive distribution framework for the Kingdom of Thailand.

The IL-6 Challenge: A Convergence of Cancer and Chronic Disease

The partnership centers on the critical clinical challenge of chronically elevated IL-6, a "master cytokine" increasingly recognized as a primary driver of cancer and chronic inflammations. An alarming rise of its population-wide prevalence took place since the pandemic, implicating public healthcare concerns. As organizations dedicated to oncology, Xylonix and Invitrocue identify IL-6 as a critical barrier to patient survival and quality of life, fuelling:

- **Cancer Progression:** Promoting metastasis, immune evasion, and systemic drug resistance.
- **Chronic Inflammation:** Serving as the primary driver for debilitating conditions such as **Rheumatoid Arthritis (RA)**, **Inflammatory Bowel Disease (IBD)**, **Long COVID** and **Chronic Pain Disorders**.

The Innovation: Kibotide™ (Zn+ γ-PGA) Bioshuttle

To address these pathologies, the partnership will utilize Kibotide™, a biotech-grade oral supplement developed by Xylonix. Kibotide™ is formulated as a Zn+**γ**PGA bioshuttle, consisting of zinc and **γ**-Polyglutamic Acid (**γ**-PGA).

Building on well-established IL-6 reducing benefits of zinc and inflammation-targeting bioshuttle technologies, Kibotide™ is designed to facilitate focused, site-specific IL-6 reduction directly at active inflammation sites. This targeted approach aims to provide significant clinical benefit without the risks associated with broad systemic immunosuppression.

Clinical Roadmap: Rheumatoid Arthritis as a Model Pathology

The companies have executed an agreement to initiate the first clinical investigations in Thailand.

- **Rationale:** The selection of RA as the primary model is supported by internal observational data demonstrating highly consistent effects in alleviating joint health symptoms.
- **Initial Focus:** The study will target patients with **Rheumatoid Arthritis (RA)** as the primary "model pathology."
- **Objective:** To quantitatively assess the ability of the Zn+ **γ**-PGA bioshuttle to reduce systemic and localized IL-6 levels and to reduce RA symptoms.

- **Expansion:** Proof of concept in RA will provide the clinical foundation to expand its applicability investigation into cancer supportive care, IBD, Long COVID, and chronic pain management.

Strategic Operations and Thai Distribution

While the clinical mission remains the priority, the partnership is supported by a robust commercial structure ensuring patient access:

- **Exclusive Distribution:** Invitrocue, via its Thailand subsidiary, serves as the exclusive distributor for Kibotide™ in Thailand.

- **Omni-Channel Access:** Exclusivity covers all channels in the country, including hospitals, clinics, pharmacies, and all digital/e-commerce platforms.

- **Operational Roles:** Invitrocue Thailand will lead the sourcing of local clinical research partners and grant opportunities, while Xylonix provides full technical dossiers and scientific support.

Leadership Commentaries

“This partnership addresses a critical gap in the management of IL-6 pathologies common in cancer, autoimmune conditions, and Long COVID, where current systemic treatments are often restricted by severe side-effects and prohibitive costs,” said Dr. Steven FANG, CEO of Invitrocue. “By utilizing Rheumatoid Arthritis as our primary model, we aim to validate the Zn+ **γ**-PGA bioshuttle as a targeted, practical intervention. Our goal is to establish a new standard of care for chronic inflammation and pain—conditions that have remained largely underserved by existing pharmaceutical options, and with potential synergies to empower biologics in severe cases.”

“Thailand’s status as a premier clinical research hub provides the ideal environment to address the post-pandemic IL-6 crisis, a widespread healthcare challenge that has intensified globally. Our internal observations have already shown highly consistent results in alleviating joint-related inflammatory symptoms among the users across Singapore, Korea, and the USA,” said Dr. Jinhyuk Fred CHUNG, CEO of Xylonix and Global CSO of Invitrocue. “By merging Xylonix’s technical innovation with Invitrocue’s clinical and commercial footprint, we are introducing an immediately accessible solution for a massive population currently without a viable answer. We are not simply entering an existing market; we are answering a new and urgent global need for safe, site-specific immune normalization.”

About Xylonix

Xylonix is a Singapore-based biotechnology company specializing in immuno-oncology. The firm focuses on the development of a first-in-class C10 *in-situ* universal cancer vaccine, and commercial products that aim at immune normalization via macrophage reprogramming, IL-6 reduction, and respiratory infection control.

About Invitrocue

Invitrocue is a world-leading precision medicine company dedicated to transforming cancer care through the integration of bio-functional 3D modeling, multi-omic molecular diagnostics, and AI-driven screening. By merging with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories, Invitrocue has established an end-to-end clinical continuum—bridging the gap between cutting-edge oncology diagnostic solutions to clinicians across Asia with licensed labs by the Ministry of Health Singapore that are also accredited by the College of American Pathologists (CAP).

For further information and inquiry, please contact:

XYLONIX	INVITROCUE	INVITROCUE THAILAND
Gregory IRVING	Steven FANG	Pongsathorn Chotikasemsri
g.irving@xylonix.io	Steven.fang@invitrocue.com	pongsathorn.cho@invitrocue.com
www.xylonix.io	www.invitrocue.com	www.invitrocue.com